



OPEN

Predicting the optimal concentration of remifentanyl for skull pin fixation with hemodynamic and analgesia nociception index monitoring

Yi-Wei Kuo¹, Ying-Tzu Chen¹, Ann-Shung Lieu², Meei-Shyuan Lee³, Yu-Feng Su¹, Hou-Chuan Lai^{4,7}✉ & Zhi-Fu Wu^{1,4,5,6,7}✉

Inadequate antinociception during skull pin fixation may cause hemodynamic instability in intracranial surgery. The optimal concentration of remifentanyl to provide adequate antinociception and stable hemodynamics during skull pin fixation under analgesia nociception index monitoring is unknown. This study is to assess the 90% effective concentration of remifentanyl for skull pin fixation under hemodynamic and analgesia nociception index monitoring. Twenty-six patients were enrolled for intracranial surgery, anesthesia was induced and maintained under total intravenous anesthesia using target-controlled infusion for remifentanyl and propofol under analgesia nociception index and bispectral index monitoring. Skull pin fixation was performed at different effect-site concentrations of remifentanyl required for Dixon's up-and-down method with a step size of 0.5 ng/ml under bispectral index 40–60. Inadequate antinociception is defined when either ANI < 30 or > 20% in hemodynamic changes from baseline (e.g. heart rate > 100 beats/min, or blood pressure > 180/100 mmHg) and the effect-site concentration of remifentanyl is considered as failure. It is considered success as ANI > 30 and < 20% hemodynamic changes from baseline simultaneously. Seven pairs of failure/success were used for probit analysis. The 90% effective concentration of remifentanyl for skull pin fixation with adequate antinociception and hemodynamic stability was 4.7 ng/ml.

Keywords Remifentanyl, Analgesia nociception index, Skull pin fixation, Intracranial surgery

Abbreviations

ABP	Arterial blood pressure
ANI	Analgesia nociception index
ANI _i	Instant-analgesia nociception index
ANI _m	Mean-analgesia nociception index
ASA	American Society of Anesthesiology
BIS	Bispectral index
BP	Blood pressure
Ce	Effect-site concentration
EC	Effective concentration
EtCO ₂	End-tidal carbon dioxide

¹Department of Anesthesiology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, No. 100, Tzyou 1st Rd., Sanmin Dist., Kaohsiung City 80756, Taiwan, ROC. ²Department of Surgery, Division of Neurosurgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC. ³School of Public Health, National Defense Medical Center, Taipei, Taiwan, ROC. ⁴Department of Anesthesiology, Tri-Service General Hospital and National Defense Medical Center, #325, Section 2, Chenggung Road, Neihu 114, Taipei, Taiwan, ROC. ⁵Department of Anesthesiology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC. ⁶Center for Regional Anesthesia and Pain Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, ROC. ⁷These authors contributed equally: Hou-Chuan Lai and Zhi-Fu Wu. ✉email: m99ane@gmail.com; aneswu@gmail.com

GA	General anesthesia
HR	Heart rate
IRB	Institutional review board
KMUH	Kaohsiung Medical University Hospital
MAP	Mean arterial pressure
SD	Standard deviation
SPI	Surgical pleth index
TCI	Target-controlled infusion
TIVA	Total intravenous anesthesia

Skull pin fixation for craniotomy elicits a significant hemodynamic response despite the optimal depth of general anesthesia (GA)¹. The changes in heart rate (HR) and blood pressure (BP) reflect an autonomic (sympathetic) response to noxious stimulation from skull pin fixation, as the scalp and the periosteum are richly innervated with nerve fibers¹. Anesthesiologists may encounter hemodynamic changes that require pharmacological intervention due to a noxious stimulus resulting from skull pin fixation. Acute arterial hypertension may lead to intracranial hemorrhage and induce intracranial hypertension and cerebral edema in patients with intracranial tumor^{2,3}. Thus, various strategies such as local anaesthetics, opioids, and scalp blocks have been used to blunt hemodynamic responses induced by skull pin fixation^{2,4–7}. Though scalp block or local infiltration may provide adequate analgesia and hemodynamic stability, it requires extra time and is not our routine practice². Total intravenous anesthesia (TIVA) is a standard and widely used method of GA, especially for evoked potential monitoring during intracranial surgery². Due to its pharmacodynamic and pharmacokinetic characteristics, such as a very short context-sensitive half-time and minimal effects on cardiovascular system, remifentanyl is a commonly used opioid in conjunction with propofol for TIVA^{2,8}.

The severity of pain and its clinical symptoms are difficult to assess in the absence of objective intraoperative analgesia monitor. Some nociception/anti-nociception balance techniques of monitoring [such as surgical pleth index (SPI) or analgesia nociception index (ANI)] were successfully introduced, which proved the utility in neuroanaesthesia regarding efficacy of pain perception^{9–13}. The ANI is a more common index that measures high-frequency component of heart rate variability on a scale from 0 (maximum of nociception) to 100 (complete analgesia)^{9–12}. Based on the published studies^{9–12}, an ANI of between 50 and 70 may correspond to adequate antinociception. Two ANI values provided by the monitor, mean-ANI (ANI_m), an average calculated over the previous 4 min, and instant-ANI (ANI_i), an average calculated over a shorter period of time (64 s)¹⁴. For skull pin fixation, Kommula et al. found that ANI values were well correlated with hemodynamics¹⁵. The ANI is superior in detecting painful stimulations compared to HR and mean arterial pressure (MAP) during propofol and remifentanyl anesthesia¹⁰. Sabourdin et al. demonstrated that ANI guidance resulted in lower remifentanyl consumption compared with standard practice under propofol and remifentanyl anesthesia¹¹.

There are several options to prevent hemodynamic perturbation during skull pinning as above mentioned, however, the optimal effective concentration (EC) of remifentanyl for skull pin fixation without inadequate antinociception and hemodynamic instability has not been thoroughly investigated. This study was designed to estimate the EC₉₀ of remifentanyl for blunting cardiovascular responses to skull pin fixation during intracranial surgery under remifentanyl/propofol TIVA with ANI and bispectral index (BIS) monitoring.

Materials and methods

This study was conducted at the Kaohsiung Medical University Hospital (KMUH), Kaohsiung, Taiwan, Republic of China. The Institutional Review Board of the KMUH approved this study (KMUHIRB-F(I)-20210156), and all methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all patients. This study was first registered at the ClinicalTrials.gov (www.clinicaltrials.gov) on 18/11/2021, with registration number NCT05125328. Twenty-six adult patients scheduled for elective intracranial surgery with skull pin fixation under intubated TIVA using a target-controlled infusion (TCI) systems (TCI, Fresenius Orchestra Primea; Fresenius Kabi AG, Bad Homburg, Germany) were enrolled in this study. The eligible patients were aged 20 to 80 years with ASA physical status I–III. The exclusion criteria for this study were as following: patients with ASA physical status ≥ IV, patients with major comorbid diseases under beta-adrenergic blocker use, patients with a pacemaker or a significant arrhythmia (eg. atrial fibrillation), patients with chronic pain, emergent surgery, and allergy to propofol or remifentanyl.

All patients were fasted overnight before the procedure, and no medications were administered before the induction of anesthesia. Each patient received standard monitoring, including electrocardiography (lead II), noninvasive BP testing, pulse oximetry, end-tidal carbon dioxide (EtCO₂) measurement, and direct radial ABP monitoring. In addition, all patients underwent monitoring for the BIS (BIS™ Complete 2-Channel Monitor, COVIDIEN, Boulder, CO, USA) and ANI (Physiodoloris®, MDoloris Medical Systems, Loos, France). Participants were preoxygenated with 6 l/min 100% oxygen via a facial mask to achieve peripheral oxygen saturation of 99–100% before induction.

Patients were induced with an effect-site concentration (Ce) of 2.0–4.0 ng/ml of remifentanyl (50 mcg/ml, Minto model) and Ce 3.0–6.0 mcg/ml of propofol (10 mg/ml; Schnider model) with continuous infusion using two separate TCI pumps. Rocuronium (0.6 mg/kg) was administered after loss of consciousness in all patients to facilitate endotracheal intubation. Anesthesia was maintained with an oxygen flow of 0.3 l/min and mixed air 0.7 l/min. The EtCO₂ was maintained at 35–45 mmHg by adjusting the ventilation rate and maximum airway pressure < 30 cmH₂O. The intraoperative administration of propofol and remifentanyl was guided by maintaining the BIS value at 40–60 and a mean (4-min moving average) ANI (ANI_m) of 50–70 during surgery.

The target Ce of remifentanyl for skull pin fixation was adjusted by using Dixon's up-and down sequential method^{16,17}. Skull pin fixation was performed when the preset remifentanyl concentration was reached and persisted at least 2 min, and the Ce of remifentanyl for the first subject was set to 6.0 ng/ml based on our clinical experience. If inadequate antinociception (ANI < 30)¹⁸ or hemodynamic instability [$>20\%$ increase in hemodynamic changes from baseline such as HR and mean arterial pressure (MAP)] or HR > 100 beats/min (bpm) or ABP > 180/100 mmHg during skull pin fixation was defined as failure; otherwise, the setting was considered successful without abovementioned situations. The next setting of remifentanyl concentration was predetermined by the response of previous patient with a higher or lower dose (0.5 ng/ml as a step size). After a failure trial, the target concentration of remifentanyl was increased by 0.5 ng/ml for next patient. Conversely, if no inadequate antinociception or hemodynamic instability was observed, the remifentanyl concentration was decreased by 0.5 mg/ml for next patient. We recorded the Ce of remifentanyl, Ce of propofol, HR, MAP, BIS, and ANI values at 5 time points as following: T0: baseline (at initial induction of GA before loss of consciousness); T1: 2 min before skull pin fixation; T2: during skull pin fixation; T3: 5 min after skull pin fixation; T4: 15 min after skull pin fixation. For patients with HR > 100 bpm or ABP > 180/100 mmHg during anesthesia, beta-blockers or anti-hypertensive agents were administered. For patients with HR < 50 bpm or ABP < 90/50 mmHg during anesthesia, atropine or ephedrine was given. After surgery, all patients were transferred to the intensive care unit. All patients were anesthetized by one anesthesiologist, and another investigator assessed them for the presence of a successful or failure response to skull pin fixation. Neither the surgeon performing skull pin fixation nor the patient was aware of the remifentanyl/propofol Ce during skull pin fixation.

Demographic data were collected and are presented as mean and standard deviation (SD). Dixon's up-and-down method needs at least six pairs of failure/success for statistical analysis, and sample size came from the basis of Dixon's method¹⁴. Seven pairs of failure/success were used for probit analysis for this study, which enabled us to derive the target remifentanyl concentration for skull pin fixation with 95% confidence limits of the mean. The EC₅₀ and EC₉₀ were estimated using the probit model. All the variables during the study period, including ANI, BIS, HR, MAP, Ce of propofol and remifentanyl at different time points were analyzed by a repeated measures analysis of variance, and the Turkey procedure was conducted as appropriate, correcting for multiple comparisons. Linear regression was performed to determine the relationship among ANI, HR, MAP, BIS or Ce of propofol and remifentanyl. A P value of < 0.05 was considered significant. The statistical tests were performed using a SPSS Statistics Version 28.0 (IBM Corp., Armonk, NY, USA).

Ethics statement

This study was conducted at the Kaohsiung Medical University Hospital (KMUH), Kaohsiung, Taiwan, Republic of China. The Institutional Review Board of the KMUH approved this study (KMUHIRB-F(I)-20210156), and all methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all patients. This study was first registered at the ClinicalTrials.gov (www.clinicaltrials.gov) on 18/11/2021, with registration number NCT05125328.

Results

Twenty-six patients were included in this study. The plots of Ce of remifentanyl associated with success or failure of skull pin fixation for each consecutive patient were shown in the Fig. 1. The patients' demographic data and the perioperative events were presented in Table 1. There were 7 male and 19 female patients with age of 59.5 ± 10.4 years, height of 159.3 ± 7.3 cm, weight of 64.9 ± 15.9 kg, anesthesia time of 299.2 ± 113.5 min, and operation time of 218.7 ± 106.2 min. There was no patient received anti-hypertensive agents or beta-blockers after adjusting remifentanyl dosage during this trial. Eight patients received ephedrine due to post-induction hypotension before this trial (Table 1).

Table 2 reported the Ce of propofol and remifentanyl, BIS values, HR, and MAP during study. Ce of propofol/remifentanyl at T0 (3.7 ± 1.1 mcg/ml; 3.1 ± 0.9 ng/ml) was significantly higher than that at T3 (2.2 ± 0.6 mcg/ml; 1.9 ± 0.5 ng/ml) and T4 (2.3 ± 1.2 mcg/ml; 1.1 ± 0.8 ng/ml). Ce of propofol at T0 (3.7 ± 1.1 mcg/ml) was significantly higher than that at T1 (2.3 ± 0.7 mcg/ml) and T2 (2.3 ± 0.7 mcg/ml). Ce of remifentanyl at T1/T2 (4.1 ± 0.9 ; 4.2 ± 0.7 ng/ml) was significantly higher than that at T3 and T4 ($P < 0.05$). BIS level at T0 (92.7 ± 7.2) was significantly higher than BIS level at T1 (49.6 ± 10.5), T2 (46.0 ± 6.6), T3 (44.6 ± 8.6), and T4 (47.0 ± 8.5). In addition, the results of T0 data (BIS of 92.7 ± 7.2 under propofol Ce of 3.7 ± 1.1 mcg/ml) were at initial induction of GA before loss of consciousness. HR at T0/T1 (75.3 ± 14.4 ; 72.2 ± 13.9 bpm) was significantly higher than HR at T3 (68.3 ± 14.1 bpm, $P < 0.05$). MAP at T2 (102.3 ± 16.6 mmHg) was significantly higher than MAP at T1 (92.2 ± 13.0 mmHg) and T3 (84.9 ± 13.3 mmHg) ($P < 0.05$) (Table 2). Finally, the Ce of propofol and remifentanyl, BIS values, HR, and MAP during study revealed significantly different at different time points ($P < 0.001$).

Table 3 compared HR, MAP, ANI, BIS, and Ce of propofol and remifentanyl between successful and failure patients during skull pin fixation. Successful patients with higher remifentanyl Ce (4.5 ± 0.6 vs. 3.8 ± 0.5 , $P = 0.004$) and ANI_i (51.1 ± 16.9 vs. 27.2 ± 7.9 , $P < 0.001$) compared with failure patients. There was no significant difference in HR, MAP, BIS, and propofol Ce between the successful and failure patients (Table 3).

Figure 2 compared ANI values at each time point. ANI_i at T1/T3/T4 (56.4 ± 14.7 ; 62.4 ± 16.8 ; 64.1 ± 18.9) was significantly higher than that at T2 (41.0 ± 18.2 ; $P < 0.05$). ANI_i at T0 (73.7 ± 11.6) was significantly higher than that at T1 and T2 ($P < 0.05$). In addition, ANI_m at T0 (74.1 ± 12.5) was significantly higher than that at T1 (57.6 ± 12.7), T2 (50.0 ± 13.5), and T3 (61.3 ± 13.3). ANI_m at T4 (68.3 ± 15.9) was significantly higher than that at T1 and T2 ($P < 0.05$), and T3 was significantly higher than that at T2 ($P < 0.05$; Fig. 2).

Figure 3 scatter plots demonstrated the correlation among HR, MAP, BIS, Ce of propofol and remifentanyl, and ANI_i. ANI_i was significantly correlated with remifentanyl Ce ($r = 0.647$, $P < 0.001$), but not HR, MAP, BIS, or propofol Ce.




Figure 1. The Ce of remifentanyl in the 26 consecutive patients in whom the skull pin fixation was attempted. Each patient's data are represented with a circle or a square; a filled circle (●) means successful skull pin fixation, a hollow square (□) means unsuccessful skull pin fixation.

Age (year)	59.5 (10.4)
Sex (Male/Female)	7/19
Height (cm)	159.3 (7.3)
Weight (kg)	64.9 (15.9)
Tumor location	
Pituitary	9
Frontal	6
Cerebellar	3
Parasagittal	2
Parietal	2
Skull base	2
Occipital	1
Temporal	1
Anesthetic time (mins)	299.2 (113.5)
Operation time (mins)	218.7 (106.2)
Ephedrine	8

Table 1. Baseline characteristics and perioperative events of patients. Values are expressed as mean (standard deviations; SD) or number except for sex. Eight patients received ephedrine due to post-induction hypotension.

Figure 4 showed the EC_{50} for adequate antinociception and cardiovascular response inhibition to skull pin fixation using remifentanyl was 4.4 ng/ml and EC_{90} was 4.7 ng/ml. Seven pairs of failure/success were used for probit analysis.

Discussion

The major finding in our study is that the effective Ce of remifentanyl at which there were 50% and 90% probabilities of successful skull pin fixation were 4.4 ng/ml and 4.7 ng/ml, respectively. Accordingly, we suggest that skull pin fixation can be performed 90% patients without noxious stimulation-induced cardiovascular response

	T0	T1	T2	T3	T4	P value
Ce of propofol (mcg/ml)	3.7 ± 1.1 [†]	2.3 ± 0.7 [#]	2.3 ± 0.7 [†]	2.2 ± 0.6 [†]	2.3 ± 1.2 [#]	<0.001
Ce of remifentanyl Ce (ng/ml)	3.1 ± 0.9 ^{*†}	4.1 ± 0.9 ^{%+}	4.2 ± 0.7 ^{▼&}	1.9 ± 0.5 ^{*▼+}	1.1 ± 0.8 ^{%&†}	<0.001
BIS	92.7 ± 7.2 [†]	49.6 ± 10.5 [†]	46.0 ± 6.6 [†]	44.6 ± 8.6 [†]	47.0 ± 8.5 [†]	<0.001
HR (bpm)	75.3 ± 14.4 [*]	72.2 ± 13.9 [†]	70.2 ± 12.5	68.3 ± 14.1 ⁺⁺	68.5 ± 12.6	<0.001
MAP (mmHg)	101.3 ± 12.4	92.2 ± 13.0 [§]	102.3 ± 16.6 ^{§▼}	84.9 ± 13.3 [▼]	94.1 ± 15.7	<0.001

Table 2. Propofol and remifentanyl effective concentration (Ce), bispectral index (BIS) values, heart rate (HR), and mean arterial pressure (MAP) during skull pin fixation. Ce indicates effect-site concentration. T0: baseline (at initial induction of general anesthesia before loss of consciousness); T1: 2 min before pin fixation; T2: during pin fixation; T3: 5 min after pin fixation; T4: 15 min after pin fixation. [†]P < 0.05 as T0 versus other time points. [@]P < 0.05 as T0 versus T2. ^{*}P < 0.05 as T0 versus T3. [†]P < 0.05 as T0 versus T4. [§]P < 0.05 as T1 versus T2. ⁺P < 0.05 as T1 versus T3. [%]P < 0.05 as T1 versus T4. [▼]P < 0.05 as T2 versus T3. [&]P < 0.05 as T2 versus T4.

	Successful	Unsuccessful	P value
N	15	11	
HR	71.1 ± 11.8	69 ± 13.4	0.683
MAP	97.6 ± 15.5	108.6 ± 15.8	0.101
AN _i	51.1 ± 16.9	27.2 ± 7.9	<0.001 [*]
BIS	44.9 ± 5.8	47.5 ± 7.4	0.359
Ce of propofol	2.4 ± 0.6	2.2 ± 0.7	0.298
Ce of remifentanyl	4.5 ± 0.6	3.8 ± 0.5	0.004 [*]

Table 3. The comparison of hemodynamics, analgesia nociception index, bispectral index, and effect-site concentrations of propofol and remifentanyl between successful and failure patients during skull pin fixation. Ce indicates effect-site concentration; AN_i indicates an instantaneous value calculated as a mobile mean of ANI over 64 s of monitoring. BIS bispectral index.




Figure 2. Comparison of analgesia nociception index (ANI) during skull pin fixation at different time points (T0: baseline; T1: 2 min before skull pin fixation; T2: during skull pin fixation; T3: 5 min after skull pin fixation and T4: 15 min after skull pin fixation). AN_i_m indicates a mean value calculated as a mobile mean of ANI over 4 min of monitoring; AN_i_i indicates an instantaneous value calculated as a mobile mean of ANI over 64 s of monitoring. ⁺⁺P < 0.05 as T0 versus T1; [@]P < 0.05 as T0 versus T2; ^{*}P < 0.05 as T0 versus T3; [§]P < 0.05 as T1 versus T2; [%]P < 0.05 as T1 versus T4; [▼]P < 0.05 as T2 versus T3; [&]P < 0.05 as T2 versus T4.




Figure 3. Scatter plots demonstrated the correlation between ANI_i and (A) heart rate (HR), (B) mean arterial pressure (MAP), (C) bispectral index (BIS), (D) Ce of propofol, and (E) Ce of remifentanyl. ANI_i was significantly correlated with remifentanyl Ce ($r=0.647$, $P<0.001$), but not HR, MAP, BIS, or propofol Ce. ANI_i indicates an instantaneous value calculated as a mobile mean of ANI over 64 s of monitoring. Ce indicates effect-site concentration.




Figure 4. Dose–response curve for remifentanyl from the probit analyses of individual concentrations and the respective patient reactions to skull pin fixation. The concentrations of remifentanyl at which there were 50% and 90% probabilities of successful skull pin fixation were 4.4 ng/ml and 4.7 ng/ml, respectively. Seven pairs of failure/success were used for probit analysis.

after adjusting remifentanyl Ce of 4.7 ng/ml under remifentanyl/propofol TCI and ANI/BIS monitoring. In addition, ANI monitoring is more sensitive on remifentanyl requirement than hemodynamics and BIS during skull pin fixation.

There is no previous literature objectively evaluating the autonomic response to noxious stimulation from skull pin application using remifentanyl/propofol TCI under ANI and BIS monitoring. Previous studies have investigated the most effective method of alleviating hemodynamic responses to skull pin fixation^{1,19–22}. The authors introduced and compared various strategies, such as intravenous opioids, local anesthetic infiltration at the pin sites, a combination of intravenous fentanyl and local anesthetic infiltration, and scalp nerve blockade. However, no consensus exists to guide anesthesiologists in attenuating cardiovascular responses to skull pin fixation. Intravenous fentanyl injection alone may not be sufficiently effective in many cases, and local anesthetic infiltration may not always be effective because sometimes the exact pin sites may not match the infiltrated scalp area. Moreover, scalp nerve block is not always effective, and its performance requires extra time and training². As mentioned previously, remifentanyl has excellent characteristics and is commonly used, along with propofol, by anesthesiologists for TIVA with a TCI system during neurosurgery. If the Ce of remifentanyl that effectively reduces hemodynamic responses to skull pin fixation is attained, the anesthesiologists can maintain a stable hemodynamic status with fewer drugs and use a simpler approach.

Previously, two similar studies were conducted to determine the EC_{50} and EC_{90} of remifentanyl necessary to minimize the cardiovascular changes due to skull pin fixation under TIVA with remifentanyl and propofol under BIS but without ANI monitoring^{2,23}. Lee et al. used the biased coin up-and-down design sequential method to calculate the remifentanyl EC_{50} of 5.33 ng/ml, the EC_{90} of 6.48 ng/ml and EC_{95} of 6.74 ng/ml². Do et al. used the Dixon up-and-down sequential allocation method to find the remifentanyl EC_{50} of 2.90 ng/ml and the EC_{95} of 4.28 ng/ml²³. Our results were similar with Do et al. reporting that the EC_{95} of remifentanyl was 4.28 ng/ml based on the same statistic method, Dixon up-and-down sequential allocation method. On the other hand, Lee et al. used the biased coin up-and-down design sequential method and kept BIS values at between 40 and 50 perioperatively, and their values were higher than Do et al.'s and our results. However, they did not use ANI monitoring during study. Though Lee et al. showed that the C_e of remifentanyl were higher than our results (6.5 vs. 4.7 ng/ml) during skull pin fixation, it might be due to gender-related differences in the C_e of remifentanyl based on our majority of female patients (43.6% vs. 73.1%), and female patients might be more sensitive to ANI monitoring²⁴ and require less opioid dosage²⁵. However, further research on gender issue is necessary. In this study, there were total 11 failure patients, two (2/11; 18.2%) failure patients with $ANI > 30$ but hemodynamic change $> 20\%$. On the other hand, nine (9/11; 81.8%) failure patients with $ANI < 30$. Among them, three patients (3/11; 27.3%) with both $ANI < 30$ and cardiovascular changes $> 20\%$, and six patients (6/11; 54.5%) with $ANI < 30$ and cardiovascular changes $< 20\%$. We also found that the ANI_i was significantly correlated with the C_e of remifentanyl ($r = 0.647$, $P < 0.001$), but not HR, MAP, BIS, or propofol C_e (Fig. 3). Therefore, our results might provide more accurate information to prevent noxious stimulation during skull pin fixation.

Several studies have evaluated ANI in identifying the pain during the intraoperative phase. ANI decreased with airway manipulation, skin incision and increased with fentanyl administration²⁶. However, the use of ANI to provide clinical benefits, such as decreased intraoperative opioid use, postoperative opioid use, and postoperative pain compared to standard practices appeared controversial²⁷. In the review, ANI-guided intraoperative opioid consumption might vary based on the type and length of the surgery associated with nociceptive stimuli, the pharmacological properties of the different anesthetics (such as propofol versus inhalation, or continuous infusion of opioid such as remifentanyl versus bolus of fentanyl), and sample sizes²⁷. Jeanne et al. found that ANI monitoring was more sensitive than hemodynamic parameters to moderate noxious stimuli under propofol anesthesia in patients undergoing laparoscopic surgery²⁸. In addition, Daccache et al. have shown that ANI can be used to adequately guide intraoperative remifentanyl administration during vascular surgery under TIVA with propofol²⁹. Theerth et al. successfully used ANI for pain monitoring in skull pin fixation under regional analgesic techniques, but not propofol/remifentanyl TIVA¹. Here, we first used propofol/remifentanyl TIVA under ANI and BIS monitoring for pain monitoring in skull pin fixation. And we found that successful patients with significantly higher C_e of remifentanyl, ANI_m , and ANI_i compared with failure patients (Table 3). However, there was no significant difference in HR, MAP, BIS, and propofol C_e between the successful and failure patients.

There were some limitations in this study. First, the sample size was small with the majority of female patients, and the results were only applicable for the Chinese and not appropriate for other populations. Second, increased C_e of propofol might reduce EC_{50} and EC_{90} of remifentanyl during procedure³⁰. Many studies have been conducted to find the C_e of propofol required for appropriate unconsciousness when TIVA was performed. Ithnin et al. reported that C_e of propofol for adequate tracheal intubating condition was 3.0 mcg/ml with C_e of remifentanyl 4.41 ng/ml³¹. Do et al. reported that C_e of propofol was maintained at 2.0 mcg/ml to keep BIS levels between 40 and 60 during head holder pinning²³. In this study, the C_e of propofol during skull pin fixation (T2) was maintained at 2.3 ± 0.7 mcg/ml to keep BIS levels between 40 and 60. Our setting was consistent with Do et al. study. On the other hand, Lee et al. showed that both the C_e of propofol at 2.9 ± 0.7 mcg/ml (to keep BIS levels between 40 and 50), and the C_e of remifentanyl were higher than our results during skull pin fixation, it might be due to age/gender-related differences in the C_e of propofol/remifentanyl based on our majority of older female patients^{24,32}. However, age might not affect the C_e of remifentanyl during surgery³³. Further studies are needed for checking effects of age and gender to C_e of propofol/remifentanyl. Third, in our clinical practice, we didn't routinely perform pin-site infiltration or scalp block for patients. However, local anesthetic infiltration might not always be effective because sometimes the exact pin sites might not match the infiltrated scalp area¹. Moreover, scalp nerve block is not always effective³⁴, and its performance required extra time and training². Further research is necessary. Fourth, there were 6 failed patients who showed $ANI < 30$ and cardiovascular changes $< 20\%$. These patients might be regarded as success when we applied them with only hemodynamic criteria. However, we increased a step size according to inadequate antinociception based on our protocol. Fortunately, increasing a step size resulted in success without any side effect following these 6 failed patients. Fifth, our protocol used ANI-guided remifentanyl administration based on our clinical experience, but not SPI or pupillometry-guided, which might be complicated for inexperienced anesthesiologists to practice⁸. However, the ANI monitor is a more common device in our hospital. Finally, we failed to aim to keep BIS above 45 during surgery, and $BIS < 45$ might result in bradycardia and hypotension and affect nociception/anti-nociception balance³⁵. Further research is necessary to check the relationship of BIS values and C_e of propofol/remifentanyl for nociception/anti-nociception balance.

Conclusions

Under ANI monitoring, adjustment of the C_e of remifentanyl to approximately 4.7 ng/ml at least 2 min before skull pin fixation could blunt noxious stimulation and provide stable cardiovascular responses in 90% of intracranial surgery ASA I–III patients while propofol TCI titrated to maintain BIS between 40 and 60.

Data availability

The original contributions presented in the study are included in the article, and further inquiries can be directed to the corresponding author.

Received: 29 September 2023; Accepted: 4 March 2024

Published online: 18 March 2024

References

- Theerth, K. A., Sriganesh, K., Chakrabarti, D., Reddy, K. R. M. & Rao, G. S. U. Analgesia nociception index and hemodynamic changes during skull pin application for supratentorial craniotomies in patients receiving scalp block versus pin-site infiltration: A randomized controlled trial. *Saudi J. Anaesth.* **13**, 306–311 (2019).
- Lee, J. M., Bahk, J. H., Lim, Y. J., Lee, J. & Lim, L. The EC90 of remifentanyl for blunting cardiovascular responses to head fixation for neurosurgery under total intravenous anesthesia with propofol and remifentanyl based on bispectral index monitoring: Estimation with the biased coin up-and-down sequential method. *BMC Anesthesiol.* **17**, 136 (2017).
- Engberg, M., Melsen, N. C., Herlevsen, P., Haraldsted, V. & Cold, G. E. Changes of blood pressure and cerebral arterio-venous oxygen content differences (AVDO2) with and without bupivacaine scalp infiltration during craniotomy. *Acta Anaesthesiol. Scand.* **34**, 346–349 (1990).
- Fu, P. H. *et al.* Association of scalp block with intraoperative hemodynamic profiles and postoperative pain outcomes at 24–48 hours following craniotomy: An updated systematic review and meta-analysis of randomized controlled studies. *Pain Pract.* **23**, 136–144 (2023).
- Carella, M., Tran, G., Bonhomme, V. L. & Franssen, C. Influence of levobupivacaine regional scalp block on hemodynamic stability, intra- and postoperative opioid consumption in supratentorial craniotomies: A randomized controlled trial. *Anesth. Analg.* **132**, 500–511 (2021).
- Geze, S., Yilmaz, A. A. & Tuzuner, F. The effect of scalp block and local infiltration on the haemodynamic and stress response to skull-pin placement for craniotomy. *Eur. J. Anaesthesiol.* **26**, 298–303 (2009).
- Arunashree, S. & Hosagoudar, P. Intravenous fentanyl 4 µg per kg administered before scalp pin application is inferior to scalp block in preventing hemodynamic changes. *Anesth. Essays Res.* **13**, 625–630 (2019).
- Stasiowski, M. J. *et al.* Adequacy of anesthesia and pupillometry for endoscopic sinus surgery. *J. Clin. Med.* **10**, 4683 (2021).
- Gruenewald, M. *et al.* Influence of nociceptive stimulation on analgesia nociception index (ANI) during propofol-remifentanyl anaesthesia. *Br. J. Anaesth.* **110**, 1024–1030 (2013).
- Funcke, S. *et al.* Validation of innovative techniques for monitoring nociception during general anesthesia: A clinical study using tetanic and intracutaneous electrical stimulation. *Anesthesiology* **127**, 272–283 (2017).
- Sabourdin, N. *et al.* Analgesia nociception index-guided remifentanyl versus standard care during propofol anesthesia: A randomized controlled trial. *J. Clin. Med.* **11**, 333 (2022).
- Upton, H. D., Ludbrook, G. L., Wing, A. & Sleight, J. W. Intraoperative “analgesia nociception index”-guided fentanyl administration during sevoflurane anesthesia in lumbar discectomy and laminectomy: A randomized clinical trial. *Anesth. Analg.* **125**, 81–90 (2017).
- Stasiowski, M. *et al.* Influence of infiltration anaesthesia on perioperative outcomes following lumbar discectomy under surgical pleth index-guided general anaesthesia: A preliminary report from a randomised controlled prospective trial. *Adv. Med. Sci.* **65**, 149–155 (2020).
- Chanques, G. *et al.* Analgesia nociception index for the assessment of pain in critically ill patients: A diagnostic accuracy study. *Br. J. Anaesth.* **119**, 812–820 (2017).
- Kommula, L. K., Bansal, S. & Umamaheswara Rao, G. S. Analgesia nociception index monitoring during supratentorial craniotomy. *J. Neurosurg. Anesthesiol.* **31**, 57–61 (2019).
- Dixon, W. J. Staircase bioassay: The up-and-down method. *Neurosci. Biobehav. Rev.* **15**, 47–50 (1991).
- Hung, N. K. *et al.* Optimal effect-site concentration of propofol for tracheal suctioning during emergence from ophthalmic surgery. *Medicine* **99**, e18669 (2020).
- Köprülü, A. Ş, Haspolat, A., Gül, Y. G. & Tanrikulu, N. Can postoperative pain be predicted? New parameter: Analgesia nociception index. *Turk. J. Med. Sci.* **50**, 49–58 (2020).
- Yildiz, K. *et al.* The effects of intravenous fentanyl and intravenous fentanyl combined with bupivacaine infiltration on the hemodynamic response to skull pin insertion. *J. Neurosurg. Anesthesiol.* **17**, 9–12 (2005).
- Ozkose, Z. *et al.* The effects of intravenous fentanyl and lidocaine infiltration on the hemodynamic response to skull pin placement. *Neurosurg. Rev.* **24**, 35–37 (2001).
- Doblar, D. D., Lim, Y. C., Baykan, N. & Frenette, L. A comparison of alfentanil, esmolol, lidocaine, and thiopental sodium on the hemodynamic response to insertion of headrest skull pins. *J. Clin. Anesth.* **8**, 31–35 (1996).
- Pinosky, M. L. *et al.* The effect of bupivacaine skull block on the hemodynamic response to craniotomy. *Anesth. Analg.* **83**, 1256–1261 (1996).
- Do, W. S., Kim, T. K., Kim, H. K. & Kim, C. H. The EC (50) of remifentanyl to minimize the cardiovascular changes during head holder pinning in neurosurgery. *Korean J. Anesthesiol.* **63**, 327–333 (2012).
- Lee, S. Y., Jeong, Y. Y., Lee, B. H. & Kim, J. E. Sex-related differences in effect-site concentration of remifentanyl for preventing anesthetic emergence cough in elderly patients. *Clin. Interv. Aging.* **13**, 81–89 (2018).
- Hung, K. C. *et al.* Usefulness of analgesia nociception index for guiding intraoperative opioid administration: A systematic review and meta-analysis. *Minerva Anesthesiol.* **89**, 74–84 (2023).
- Ledowski, T., Averhoff, L., Tiong, W. S. & Lee, C. Analgesia nociception index (ANI) to predict intraoperative haemodynamic changes: Results of a pilot investigation. *Acta Anaesthesiol. Scand.* **58**, 74–79 (2014).
- Hum, B. *et al.* The validity and applications of the analgesia nociception index: A narrative review. *Front. Surg.* **10**, 1234246 (2023).
- Jeanne, M., Clément, C., De Jonckheere, J., Logier, R. & Tavernier, B. Variations of the analgesia nociception index during general anaesthesia for laparoscopic abdominal surgery. *J. Clin. Monit. Comput.* **26**, 289–294 (2012).
- Daccache, G. *et al.* A targeted remifentanyl administration protocol based on the Analgesia Nociception Index during vascular surgery. *Anaesth. Crit. Care Pain Med.* **36**, 229–232 (2016).
- Cho, S. Y., Lee, C. W., Park, H. J., Park, S. H. & Jeon, W. J. Increased effect-site concentration of propofol reduces EC50 of remifentanyl for successful intubation using the Shikani optical stylet without neuromuscular blockade. *Soonchunhyang Med. Sci.* **25**, 104–109 (2019).
- Ithin, F., Lim, Y., Shah, M., Shen, L. & Sia, A. T. Tracheal intubating conditions using propofol and remifentanyl target-controlled infusion: A comparison of remifentanyl EC50 for glidescope and macintosh. *Eur. J. Anaesthesiol.* **26**, 223–228 (2009).
- Koo, B. N. *et al.* A pharmacodynamic analysis of factors affecting recovery from anesthesia with propofol-remifentanyl target controlled infusion. *Acta Pharmacol. Sin.* **33**, 1080–1084 (2012).
- Kim, H. Y. *et al.* Effects of age on effect-site concentration of remifentanyl for suppressing anesthetic emergence cough in male patients undergoing laparoscopic cholecystectomy. *Clin. Interv. Aging* **13**, 1053–1060 (2018).

34. Stasiowski, M. J. *et al.* Risk factors for occurrence of failed interscalene brachial plexus blocks for shoulder arthroscopy using 20 mL 0.5% ropivacaine: A randomised trial. *Anaesthesiol. Intensive Ther.* **50**, 263–269 (2018).
35. Win, N. N., Kohase, H., Miyamoto, T. & Umino, M. Decreased bispectral index as an indicator of syncope before hypotension and bradycardia in two patients with needle phobia. *Br. J. Anaesth.* **91**, 749–752 (2003).

Author contributions

Study design: H.-C.L., Z.-F.W.; conduct of the study: Y.-W.K., Y.-T.C., A.-S.L., Y.-F.S., Z.-F.W.; data analysis: M.-S.L.; data collection: Y.-W.K., Y.-T.C., A.-S.L., Y.-F.S.; preparation of the manuscript: Y.-W.K., M.-S.L., Z.-F.W., H.-C.L.; writing of the manuscript: Y.-W.K., Z.-F.W., H.-C.L.; all authors read and approved the final version of the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to H.-C.L. or Z.-F.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024